Biologic vs Small Molecule and the Peptide Boundary
Whether a peptide is regulated as a drug or as a biologic turns on a 40 amino acid threshold, and that single number decides which approval route and which copy pathway apply to it.
The Public Health Service Act governs biological products while the Federal Food, Drug, and Cosmetic Act governs drugs, and FDA's 2020 final rule defining the term biological product fixed the boundary for amino acid polymers. A protein is any alpha amino acid polymer with a specific, defined sequence greater than 40 amino acids. At or below 40 residues a molecule is a peptide and is regulated as a drug; above that line it is a biologic and requires a licence.
The numbers are unforgiving in both directions. Semaglutide and liraglutide at 31 residues, teriparatide at 34 and teduglutide at 33 are all drugs approved under new drug applications. Insulin, at 51 residues across two chains, is a biologic, and in March 2020 insulin, human growth hormone, glucagon, chorionic gonadotropin and several others transitioned by statute from applications to deemed licences. The same rule stopped treating chemically synthesised polypeptides as a separate case, so route of manufacture no longer decides the category.
Everything downstream follows from which side of 40 a molecule falls. A drug can be copied through an abbreviated application and substituted at the counter; a biologic can only be copied through the 351(k) biosimilar pathway with its own comparative analytical and clinical programme. Exclusivity differs too, five years of new chemical entity protection against twelve years of reference product exclusivity.
The error is treating the threshold as a statement about biology. Nothing physical changes between 40 and 41 residues; the line is administrative, chosen because it was workable. Marketing that calls a 30-residue synthetic peptide a biologic to borrow the word's gravity, and the opposite argument that a peptide is a mere chemical and therefore lightly regulated, both misuse the same line.